Literature DB >> 8308774

Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

P J Clements1, P A Lachenbruch, J R Seibold, B Zee, V D Steen, P Brennan, A J Silman, N Allegar, J Varga, M Massa.   

Abstract

OBJECTIVE: Using data from 3 independent studies, to quantify the interobserver reliability of semi-quantitative skin scoring methods (the original and the modified Rodnan skin thickness scores) used to assess the degree and extent of cutaneous thickening in systemic sclerosis (SSc).
METHOD: Interobserver variability of the original Rodnan skin thickness score method (cutaneous thickness assessed in 26 body surface areas using a 0-4 scale) was evaluated in one study. The modified Rodnan method (cutaneous thickness assessed in 17 body surface areas using a 0-3 scale) was evaluated in 2 studies. In all 3 studies, each patient's skin thickness was assessed by 6 or 7 observers in a blinded fashion.
RESULTS: The overall within patient standard deviations were not statistically different in all 3 studies (5.4, 4.6 and 4.6) irrespective of the overall mean skin thickness scores (26.6, 18.3 and 17.7). With the original Rodnan technique, the within patient standard deviation tended to be higher in patients with higher skin thickness scores. In the 2 studies which used the modified technique, no significant differences in within patient standard deviation were noted between high and low skin thickness scores.
CONCLUSIONS: Three independent studies demonstrate that the Rodnan skin thickness scoring techniques are reproducible among different observers (the within patient standard deviation being consistently about 5 units). Our data provide valuable information needed for sample size calculations for SSc trials in which skin thickness score is an outcome variable.

Entities:  

Mesh:

Year:  1993        PMID: 8308774

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  121 in total

1.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.

Authors:  Nicolas Richard; Marie Hudson; Mianbo Wang; Geneviève Gyger; Susanna Proudman; Wendy Stevens; Mandana Nikpour; Murray Baron
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

Review 2.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

Review 3.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

4.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

5.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

6.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

7.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

Review 8.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

9.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

Review 10.  Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of the literature.

Authors:  B Vasta; V Flower; C Bucciarelli-Ducci; S Brown; E Korendowych; N J McHugh; J D Pauling
Journal:  Clin Rheumatol       Date:  2013-10-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.